Tanya Otsuka's vision for public service was forged early, borne of her grandparents' experience with injustice. "They were actually both in prison as children during World War II, because they ...

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.

ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals ...

Otsuka licensed rights to Lupkynis in various ex-US markets including the EU, Japan and the UK in 2020, with Aurinia retaining rights to the drug in the US and its home market of Canada.

Esperion (ESPR) announced that Otsuka Pharmaceutical (OSUKF) has submitted a New Drug Application, NDA, to the Japanese Ministry of Health, Labour and Welfare, MHLW, for the manufacture and sale ...

Global Digital Therapeutics Product Development at Otsuka Precision Health, Inc. (OPH). “It’s imperative that we create treatments that meet patients where they’re at, especially when it ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...